Integrating Experimental And Computational Pharmacology For Intelligent Drug Design

InterAx Biotech and Lundbeck A/S entered an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform

Switzerland – Denmark, April 2019 Villigen
InterAx Biotech AG announced today that it has entered an agreement with Lundbeck A/S to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform. InterAx and Lundbeck will combine their expertise in the characterization of drug candidates for an undisclosed target. “We are delighted to assist Lundbeck in their quest to identify compounds with superior biological properties for their target receptor with our unique technology”, says Maria Waldhoer, CSO at InterAx. Financial terms of the partnership were not disclosed.

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, Lundbeck A/S has been at the forefront of research within neuroscience.

About InterAx
InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company is uniquely positioned to assist drug candidate design and selection for G protein-coupled receptors in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in house-derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms.

My Image